• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

贝特类药物的多效性作用。

Pleiotropic effects of fibrates.

作者信息

Chinetti-Gbaguidi Giulia, Fruchart Jean Charles, Staels Bart

机构信息

UR 545 INSERM, Institut Pasteur de Lille, 1 rue Calmette BP245, 59019 Lille, France.

出版信息

Curr Atheroscler Rep. 2005 Sep;7(5):396-401. doi: 10.1007/s11883-005-0053-x.

DOI:10.1007/s11883-005-0053-x
PMID:16105484
Abstract

Fibrates are a widely used class of hypolipidemic drugs. The effects of fibrates are mediated through the activation of the transcription factor peroxisome proliferator-activated receptor a (PPARa). Fibrates act to modulate the transcription of genes that encode proteins controlling lipid transport and metabolism. Fibrates also exert pleiotropic anti-inflammatory effects by down regulating expression of genes encoding inflammatory cytokines and acute phase response proteins. These combined actions translate into clinical benefit as demonstrated by the reduction in cardiovascular morbidity and mortality in primary and secondary intervention trials.

摘要

贝特类药物是一类广泛使用的降血脂药物。贝特类药物的作用是通过激活转录因子过氧化物酶体增殖物激活受体α(PPARα)介导的。贝特类药物作用于调节编码控制脂质转运和代谢蛋白质的基因的转录。贝特类药物还通过下调编码炎性细胞因子和急性期反应蛋白的基因表达发挥多效抗炎作用。如在一级和二级干预试验中所证明的,这些联合作用转化为临床益处,表现为心血管发病率和死亡率的降低。

相似文献

1
Pleiotropic effects of fibrates.贝特类药物的多效性作用。
Curr Atheroscler Rep. 2005 Sep;7(5):396-401. doi: 10.1007/s11883-005-0053-x.
2
Fibrates consistently lower risk of cardiovascular events across high-risk groups.贝特类药物持续降低高危人群发生心血管事件的风险。
Cardiovasc J Afr. 2010 May-Jun;21(3):174.
3
[Fibrates in the light of large clinical trials].基于大型临床试验的贝特类药物
Pol Merkur Lekarski. 2015 Apr;38(226):222-7.
4
Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.他汀类药物与过氧化物酶体增殖物激活受体α在心血管疾病中的相互作用:临床证据与基本机制
Trends Cardiovasc Med. 2008 Apr;18(3):73-8. doi: 10.1016/j.tcm.2008.01.001.
5
[Nuclear receptors PPARalpha].核受体过氧化物酶体增殖物激活受体α
Vnitr Lek. 2006 Jun;52(6):628-31.
6
Fibrates in CVD: a step towards personalised medicine.心血管疾病中的贝特类药物:迈向个性化医疗的一步。
Lancet. 2010 May 29;375(9729):1847-8. doi: 10.1016/S0140-6736(10)60758-1.
7
Fibrate therapy: an update.贝特类药物治疗:最新进展
Cardiol Rev. 2008 May-Jun;16(3):129-41. doi: 10.1097/CRD.0b013e31816b43d3.
8
Fibrates: where are we now?贝特类药物:我们如今处于什么阶段?
Ther Adv Cardiovasc Dis. 2009 Feb;3(1):91-6. doi: 10.1177/1753944708096281.
9
Fibrates, dyslipoproteinaemia and cardiovascular disease.贝特类药物、血脂蛋白异常血症与心血管疾病
Curr Opin Lipidol. 1999 Dec;10(6):561-74. doi: 10.1097/00041433-199912000-00011.
10
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.贝特类药物在调节甘油三酯和高密度脂蛋白胆固醇代谢中的作用机制。
Drugs Today (Barc). 2006 Jan;42(1):39-64. doi: 10.1358/dot.2006.42.1.963528.

引用本文的文献

1
Fibrinogen and a Triad of Thrombosis, Inflammation, and the Renin-Angiotensin System in Premature Coronary Artery Disease in Women: A New Insight into Sex-Related Differences in the Pathogenesis of the Disease.纤维蛋白原与血栓形成、炎症和肾素-血管紧张素系统三联征在女性早发冠心病中的作用:对疾病发病机制中性别差异的新认识。
Biomolecules. 2021 Jul 15;11(7):1036. doi: 10.3390/biom11071036.
2
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.颈动脉内中膜厚度进展作为心血管风险的替代标志物:涉及 100667 名患者的 119 项临床试验的荟萃分析。
Circulation. 2020 Aug 18;142(7):621-642. doi: 10.1161/CIRCULATIONAHA.120.046361. Epub 2020 Jun 17.
3

本文引用的文献

1
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).在一项针对2型糖尿病的安慰剂对照研究中,非诺贝特在3年内减少了微量白蛋白尿的进展:糖尿病动脉粥样硬化干预研究(DAIS)的结果。
Am J Kidney Dis. 2005 Mar;45(3):485-93. doi: 10.1053/j.ajkd.2004.11.004.
2
Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.丙型肝炎病毒感染期间过氧化物酶体增殖物激活受体α的表达受损。
Gastroenterology. 2005 Feb;128(2):334-42. doi: 10.1053/j.gastro.2004.11.016.
3
Gemfibrozil reduces lipid accumulation in SMMC-7721 cells via the involvement of PPARα and SREBP1.
吉非贝齐通过过氧化物酶体增殖物激活受体α(PPARα)和固醇调节元件结合蛋白1(SREBP1)减少SMMC - 7721细胞中的脂质积累。
Exp Ther Med. 2019 Feb;17(2):1282-1289. doi: 10.3892/etm.2018.7046. Epub 2018 Dec 5.
4
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles.降脂药物在调节胆固醇颗粒形态方面的差异效应。
J Vis Exp. 2017 Nov 10(129):56596. doi: 10.3791/56596.
5
The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.贝特类药物吉非贝齐是可溶性鸟苷酸环化酶的一种不依赖一氧化氮和血红素的激活剂:体外研究
Br J Pharmacol. 2015 May;172(9):2316-29. doi: 10.1111/bph.13055. Epub 2015 Feb 10.
6
Megalin/LRP2 expression is induced by peroxisome proliferator-activated receptor -alpha and -gamma: implications for PPARs' roles in renal function.巨胞饮受体/LRP2 的表达受过氧化物酶体增殖物激活受体-α和 -γ诱导:提示 PPARs 在肾功能中的作用。
PLoS One. 2011 Feb 2;6(2):e16794. doi: 10.1371/journal.pone.0016794.
7
peroxisome proliferator-activated receptor alpha activation-mediated regulation of endothelin-1 production via nitric oxide and protein kinase C signaling pathways in piglet cerebral microvascular endothelial cell culture.过氧化物酶体增殖物激活受体α激活介导的通过一氧化氮和蛋白激酶C信号通路对仔猪脑微血管内皮细胞培养中内皮素-1产生的调节
J Pharmacol Exp Ther. 2007 Feb;320(2):774-81. doi: 10.1124/jpet.106.104992. Epub 2006 Nov 14.
8
Apolipoprotein A-I and risk for cardiovascular diseases.载脂蛋白A-I与心血管疾病风险
Curr Atheroscler Rep. 2006 Sep;8(5):365-73. doi: 10.1007/s11883-006-0033-9.
9
Fibrate therapy in patients with metabolic syndrome and diabetes mellitus.代谢综合征和糖尿病患者的贝特类药物治疗
Curr Atheroscler Rep. 2006 Sep;8(5):356-64. doi: 10.1007/s11883-006-0032-x.
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
非诺贝特与他汀类药物联用对比吉非贝齐与任何他汀类药物联用导致横纹肌溶解的报告率。
Am J Cardiol. 2005 Jan 1;95(1):120-2. doi: 10.1016/j.amjcard.2004.08.076.
4
Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.吉非贝齐和非诺贝特通过选择性过氧化物酶体增殖物激活受体α调节对人载脂蛋白A-I的影响
Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):585-91. doi: 10.1161/01.ATV.0000154140.73570.00. Epub 2004 Dec 23.
5
Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.他汀类药物与贝特类药物联合治疗混合性高脂血症:对一些新的危险因素的影响。
Thromb Haemost. 2004 Nov;92(5):1129-35. doi: 10.1160/TH03-04-0250.
6
Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties.过氧化物酶体增殖物激活受体α诱导巨噬细胞中的NADPH氧化酶活性,导致具有PPAR-α激活特性的低密度脂蛋白生成。
Circ Res. 2004 Dec 10;95(12):1174-82. doi: 10.1161/01.RES.0000150594.95988.45. Epub 2004 Nov 11.
7
C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells.C反应蛋白诱导人血管内皮细胞中CD40-CD40L的表达及洛伐他汀和非诺贝特对其的影响
Biol Pharm Bull. 2004 Oct;27(10):1537-43. doi: 10.1248/bpb.27.1537.
8
The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia.他汀类药物和贝特类药物对原发性II型血脂异常患者γ-干扰素和白细胞介素-2释放的影响。
Atherosclerosis. 2004 Oct;176(2):327-35. doi: 10.1016/j.atherosclerosis.2004.05.009.
9
Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity.抗高血压和降血脂药物对血浆及高密度脂蛋白相关血小板活化因子 - 乙酰水解酶活性的影响。
J Cardiovasc Pharmacol Ther. 2004 Jun;9(2):91-5. doi: 10.1177/107424840400900204.
10
PPARalpha governs glycerol metabolism.过氧化物酶体增殖物激活受体α调控甘油代谢。
J Clin Invest. 2004 Jul;114(1):94-103. doi: 10.1172/JCI20468.